Role of P-glycoprotein in the efflux of raltegravir from human intestinal cells and CD4+ T-cells as an interaction target for anti-HIV agents

Biochemical and Biophysical Research Communications

Volumn 439, Issue 2, 2013, Pages 221-227

  Hashiguchi, Yumi ^a,c   Hamada, Akinobu ^b   Shinohara, Takashi ^a   Tsuchiya, Kiyoto ^d   Jono, Hirofumi ^a,c   Saito, Hideyuki ^a,c  

^a KUMAMOTO UNIVERSITY   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^c KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

^d NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

Drug interactions; Intestinal absorption; P glycoprotein; Raltegravir; SLC transporters; T cell

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; EFAVIRENZ; LOPINAVIR; MULTIDRUG RESISTANCE PROTEIN; NELFINAVIR; NEVIRAPINE; RALTEGRAVIR; RITONAVIR; ZIDOVUDINE;

ANIMAL CELL; ARTICLE; CD4+ T LYMPHOCYTE; DRUG TRANSPORT; EPITHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; INTESTINE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSCYTOSIS;

ABC; ACETOXYMETHYL ESTER; AM; AMPRENAVIR; APV; ATAZANAVIR; ATP-BINDING CASSETTE; ATV; BCRP; BOVINE SERUM ALBUMIN; BREAST CANCER RESISTANCE PROTEIN; BSA; CSA; CYCLOSPORINE A; CYP; CYTOCHROME P450; DARUNAVIR; DMEM; DRUG INTERACTIONS; DRV; DULBECCO'S MODIFIED EAGLE'S MEDIUM; EFAVIRENZ; EFV; FBS; FETAL BOVINE SERUM; HAART; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; INTESTINAL ABSORPTION; LOPINAVIR; LPV; MRP; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEAA; NELFINAVIR; NEVIRAPINE; NFV; NON-ESSENTIAL AMINO ACID; NVP; OAT; OATP; OCT; ORGANIC ANION TRANSPORTER; ORGANIC ANION-TRANSPORTING POLYPEPTIDE; ORGANIC CATION TRANSPORTER; P-GLYCOPROTEIN; P-GP; RAL; RALTEGRAVIR; RITONAVIR; RTV; SLC; SLC TRANSPORTERS; SOLUTE CARRIER; T-CELL; UGT; URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE; ZDV; ZIDOVUDINE;

ANIMALS; ANTI-HIV AGENTS; CACO-2 CELLS; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; FLUORESCEINS; HUMANS; INTESTINAL MUCOSA; P-GLYCOPROTEIN; PYRROLIDINONES; SWINE; TRANSFECTION;

SUS;

EID: 84884291901     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.08.054     Document Type: Article

References (27)

1. Bartlett J.A., Fath M.J., Demasi R., Hermes A., Quinn J., Mondou E., Rousseau F. An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. AIDS 2006, 20:2051-2064.
2. Piacenti F.J. An update and review of antiretroviral therapy. Pharmacotherapy 2006, 26:1111-1133.
3. Kozal M.J., Hullsiek K.H., Macarthur R.D., Berg-Wolf M., Peng G., Xiang Y., Baxter J.D., Uy J., Telzak E.E., Novak R.M. The incidence of HIV drug resistance and its impact on progression of HIV disease among antiretroviral-naive participants started on three different antiretroviral therapy strategies. HIV Clin. Trials 2007, 8:357-370.
4. Siliciano J.D., Siliciano R.F. A long-term latent reservoir for HIV-1: discovery and clinical implications. J. Antimicrob. Chemother. 2004, 54:6-9.
5. Barbaro G. Highly active antiretroviral therapy-associated metabolic syndrome: pathogenesis and cardiovascular risk. Am. J. Ther. 2006, 13:248-260.
6. Haugaard S.B. Toxic metabolic syndrome associated with HAART. Expert Opin. Drug Metab. Toxicol. 2006, 2:429-445.
7. Kassahun K., McIntosh I., Cui D., Hreniuk D., Merschman S., Lasseter K., Azrolan N., Iwamoto M., Wagner J.A., Wenning L.A. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab. Dispos. 2007, 35:1657-1663.
8. Kim R.B., Fromm M.F., Wandel C., Leake B., Wood A.J., Roden D.M., Wilkinson G.R. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 1998, 101:289-294.
9. Janneh O., Jones E., Chandler B., Owen A., Khoo S.H. Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes. J. Antimicrob. Chemother. 2007, 60:987-993.
10. Janneh O., Owen A., Chandler B., Hartkoorn R.C., Hart C.A., Bray P.G., Ward S.A., Back D.J., Khoo S.H. Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS 2005, 19:2097-2102.
11. V.E. Demby, K.A. Harmon, M. Naqwe, J.E. Humphreys, M. Wire, J.W. Polli, OATP1B1, OATP1B3 and BCRP transporter characterization for fosamprenavir, amprenavir and lopinavir, in: The AAPS Annual Meeting, Abstract Number 2355. American Association of Pharmaceutical Scientists, Arlington, VA.
12. Jung N., Lehmann C., Rubbert A., Knispel M., Hartmann P., van Lunzen J., Stellbrink H.J., Faetkenheuer G. D Taubert, Relevance of the organic cation transporters 1 and 2 for antiretroviral drug therapy in human immunodeficiency virus infection. Drug Metab. Dispos. 2008, 36:1616-1623.
13. Kis O., Robillard K., Chan G.N., Bendayan R. The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters. Trends Pharmacol. Sci. 2010, 31:22-35.
14. Matsumoto S., Saito H., Inui K. Transport characteristics of ceftibuten, a new cephaloporin antibiotic, via the apical H+/dipeptide cotransport system in human intestinal cell line Caco-2: regulation by cell growth. Pharm. Res. 1995, 12:1483-1487.
15. Inui K., Yamamoto M., Saito H. Transepithelial transport of oral cephalosporins by monolayers of intestinal epithelial cell line Caco-2: specific transport systems in apical and basolateral membranes. J. Pharmacol. Exp. Ther. 1992, 261:195-201.
16. Hamada A., Miyano H., Watanabe H., Saito H. Interaction of imatinib mesilate with human P-glycoprotein. J. Pharmacol. Exp. Ther. 2003, 307:824-828.
17. Rittweger M., Arasteh K. Clinical pharmacokinetics of darunavir. Clin. Pharmacokinet. 2007, 46:739-756.
18. Fujimoto H., Higuchi M., Watanabe H., Koh Y., Ghosh A.K., Mitsuya H., Tanoue N., Hamada A., Saito H. P-glycoprotein mediates efflux transport of darunavir in human intestinal Caco-2 and ABCB1 gene-transfected renal LLC-PK1 cell lines. Biol. Pharm. Bull. 2009, 32:1588-1593.
19. Fayet Mello A., Buclin T., Franc C., Colombo S., Cruchon S., Guignard N., Biollaz J., Telenti A., Decosterd L.A., Cavassini M. Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration. J. Antimicrob. Chemother. 2011, 66:1573-1581.
20. Grinspoon S., Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N. Engl. J. Med. 2005, 352:48-62.
21. Neuvonen P.J., Niemi M., Backman J.T. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin. Pharmacol. Ther. 2006, 80:565-581.
22. Niemi M. Transporter pharmacogenetics and statin toxicity. Clin. Pharmacol. Ther. 2010, 87:130-133.
23. W.S. Kwan, R.C. Hartkoorn, E. Salcedo-Sora, P. Bray, S. Khoo, D.J. Back, A. Owen, Determining the substrate specificities of SLCO1A2 and SLCO1B1 for antiretroviral drugs [Abstract], in: Ninth International Workshop on Clinical Pharmacology of HIV Therapy 2008, O4.
24. Nakai D., Nakagomi R., Furuta Y., Tokui T., Abe T., Ikeda T., Nishimura K. Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. J. Pharmacol. Exp. Ther. 2001, 297:861-867.
25. Hirano M., Maeda K., Shitara Y., Sugiyama Y. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J. Pharmacol. Exp. Ther. 2004, 311:139-146.
26. Zembruski N.C., Büchel G., Jödicke L., Herzog M., Haefeli W.E., Weiss J. Potential of novel antiretrovirals to modulate expression and function of drug transporters in vitro. J. Antimicrob. Chemother. 2011, 66:802-812.
27. Moss D.M., Kwan W.S., Liptrott N.J., Smith D.L., Siccardi M., Khoo S.H., Back D.J., Owen A. Raltegravir is a substrate for SLC22A6: a putative mechanism for the interaction between raltegravir and tenofovir. Antimicrob. Agents Chemother. 2011, 55:879-887.